Failed Verubecestat Trial May Call into Question Beta-amyloid Theory in Alzheimer’s, Study Suggests

Failed Verubecestat Trial May Call into Question Beta-amyloid Theory in Alzheimer’s, Study Suggests
Verubecestat (MK-8931) indeed failed to slow cognitive and functional decline in mild-to-moderate Alzheimer’s patients despite some reduction in beta-amyloid levels seen, final results of a Phase 2/3 study closed early by Merck for lack of efficacy confirmed. The researchers behind this study suggested these findings may call into question whether the amyloid hypothesis of Alzheimer’s is

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

  1. DANTE MARCIANI says:

    This failure is another example of self-fulfilled prophesies. Twenty years ago it was shown that the agent causing Alzheimer’s was not the plaque, but the soluble toxic amyloid-beta oligomers. Since then, many papers have shown that such is the case; yet, the obsession with plaque continues adding confusion and slowing down progress. From several publications we can deduct that in AD, prevention will be answer; thus the efforts should be focus on the causative agent, i.e. the soluble cytotoxic amyloid oligomers, rather than on a dubious marker of the disease, i.e. plaque.

Leave a Comment

Your email address will not be published. Required fields are marked *